Adeona appoints senior VP of R&D: Ann Arbor-based Adeona Pharmaceuticals, Inc. (Amex: AEN), a developer of medicines for serious central nervous system diseases, announced the appointment of George J. Brewer, M.D., as senior vice president of research and development. Brewer joins the Adeona management team after serving as the chairman of the company’s scientific advisory Board for seven years. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan. He was a member of the National Science Council’s “Committee on Copper in Drinking Water” convened at the request of the Environmental Protection Agency in 2000 to consider the issue of what level of copper in drinking water could be considered safe. Brewer has published over 500 scientific papers, several books and is the inventor of oral zinc therapy approved by the Food & Drug Administration (FDA) in 1997, now standard of care for chronic Wilson’s disease. The study coordinators at the three clinical sites conducting Adeona’s study evaluating reaZin (zinc cysteine) for the dietary management of Alzheimer’s disease and mild cognitive impairment continue the follow-up appointments with the patients enrolled in this study. Adeona has also contracted a replacement clinical trial associate to monitor the study on behalf of the company. Patients are scheduled to complete their final study visits by the end of March 2011. As previously announced, Adeona plans to present the results of its pivotal clinical trial in a poster presentation at the American Academy of Neurology Annual Meeting on April 14 at the Hawaii Convention Center in Honolulu, Hawaii. A concurrent press release will also be distributed. More at www.adeonapharma.com.